medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2021, Number 11

<< Back Next >>

Ginecol Obstet Mex 2021; 89 (11)

Ovaric stromal hypertecosis: a case report

Mandón-Ortiz MA, Sepúlveda-Agudelo J

Language: Spanish
References: 31
Page: 905-912
PDF size: 238.86 Kb.


ABSTRACT

Background: Ovarian stromal hyperthecosis is a rare ovarian androgenizing tumor that can manifest as hyperandrogenism, endometrial carcinoma, obesity and hypertension. Only a few case reports and small case series are found in the literature.
Clinical case: 20-year-old patient with continuous vaginal bleeding, hirsutism, clitoromegaly, and android implantation of pubic and facial hair. Ultrasonography of the right ovary showed a solid lesion inside the ovary. Elevated concentrations of free testosterone, testosterone and hydroxyprogesterone. An ovarian androgenizing tumor was suspected. A laparoscopic right salpingo-oophorectomy was performed. The pathology report was ovarian parenchyma with extensive nests of luteinized stromal cells with stromal hyperplasia. Diagnosis: stromal hyperthecosis.
Conclusion: In the coexistence of signs of virilization, alteration in the regularity and frequency of the menstrual cycle, with high concentrations of androgens and an ovarian tumor lesion in the ultrasound study, ovarian stromal hyperthecosis should be suspected. The treatment of choice is surgical resection of the affected ovary. Due to the low malignant potential of these lesions, laparoscopic access can be considered.


REFERENCES

  1. Pelusi C, Forlani G, Zanotti L, Gambineri A, et al. No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours. Clin Endocrinol (Oxf) 2013; 78 (4): 533-8. doi: 10.1111/j.1365-2265.2012.04438.x

  2. Cohen I, Nabriski D, Fishman A. Noninvasive test for the diagnosis of ovarian hormone-secreting-neoplasm in postmenopausal women. Gynecol Oncol Reports 2016; 15: 12-5. doi: 10.1016/j.gore.2015.06.002

  3. Madariaga L. A, Araujo Q. M, Gil M. M, Rendón P. G, et al. Tumores virilizantes del ovario: Presentación de dos casos manejados mediante cirugía por monopuerto. Rev Chil Obstet Ginecol 2015; 80 (2): 156-60. doi:10.4067/S0717- 75262015000200010

  4. Taylor L, Ayers JW, Gross MD, Peterson EP, et al. Diagnostic considerations in virilization: iodomethyl-norcholesterol scanning in the localization of androgen secreting tumors. Fertil Steril 1986; 46 (6): 1005-10. doi: 10.1016/S0015- 0282(16)49871-7

  5. Brojeni NR, Salehian B. Androgen secreting ovarian tumors. MOJ Womens Health. 2017; 5 (6): 327-30. doi: 10.15406/ mojwh.2017.05.00145

  6. Rousset P, Gompel A, Christin-Maitre S, Pugeat M, et al. Ovarian hyperthecosis on grayscale and color Doppler ultrasound. Ultrasound Obstet Gynecol 2008; 32 (5): 694- 99. doi: 10.1002/uog.6131

  7. Boss Jh, Scully RE, Wegner KH, et al. Structural variations in the adult ovary-clinical significance. Obstet Gynecol.1965; 25: 747-64.

  8. Kurman RJ, Carcangiu ML, Herrington CS. World Health Organisation Classification of Tumours of the Female Reproductive Organs. 4th Revised ed. International Agency for Research on Cancer 2014; 4 (6).

  9. Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, et al. Epidemiology, diagnosis and management of hirsutism: A consensus statement by the androgen excess and polycystic ovary syndrome society. Hum Reprod Update 2012; 18 (2): 146-70. doi:10.1093/humupd/dmr042

  10. Robert E. Scully, Robert H. Young and Philip B. Clement. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube and Broad Ligament. Atlas of Tumor Pathology. Third Series, Fascicle 23. Journal of Pathology 1999; 189 (1): 145. doi:10.1002/(SICI)1096-9896(199909)189:1<145::AIDPATH420> 3.0.CO;2-F

  11. Goldman J, Kapadia L. Virilization in a postmenopausal woman due to ovarian stromal hyperthecosis. Postgraduate Medical Journal 1991; 67 (785): 304-6. doi: 10.1136/ pgmj.67.785.304

  12. Agorastos T, Argyriadis N, Fraggidis G, Vakiani A, et al. Postmenopausal virilization due to ovarian hyperthecosis. Arch Gynecol Obstet 1995; 256 (4): 209-11. doi: 10.1007/ BF00634494

  13. Nagamani M, Urban RJ. Increased expression of messenger ribonucleic acid encoding cytochrome P450 cholesterol side-chain cleavage and P450 17alpha-hydroxylase enzymes in ovarian hyperthecosis. Fertil Steril 1999; 71 (2): 328-33. doi: 10.1016/s0015-0282(98)00464-6

  14. Belisle S, Lehoux JG, Benard B, Ainmelk Y. Ovarian hyperthecosis: in vivo and in vitro correlations of the androgen profile. Obstet Gynecol 1981; 57 ( Suppl 6): 70S-75S.

  15. Beksac S, Selcuk I, Boyraz G, Guner G, et al. Two patients with marginal symptoms showing hyperthecosis at the edge of malignancy: presentation of two cases. J Turk Ger Gynecol Assoc 2013; 14 (3): 182-5. doi: 10.5152/jtgga.2013.88964

  16. Barth JH, Jenkins M, Belchetz PE. Ovarian hyperthecosis, diabetes and hirsuties in post-menopausal women. Clin Endocrinol (Oxf) 1997; 46 (2): 123-8. doi:10.1046/j.1365- 2265.1997.1050916.x

  17. Clement PB, Irving JA. Nonneoplastic lesions of the ovary. In: Kurman RJ (ed). Blaustein’s Pathology of the Female Genital Tract. 5th ed. 2002; 579-624 doi:10.1007/978-1- 4419-0489-8_12

  18. Hughesdon PE. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called “hyperthecosis” Obstet Gynecol Surv 1982; 37: 59-77. doi: 10.1097/00006254-198202000-00001

  19. Sasano H, Fukunaga M, Rojas M, Silverberg SG.Hyperthecosis of the Ovary. Clinicopathologic Study of 19 Cases with Immunohistochemical Analysis of Steroidogenic Enzymes. Int J of Gynecol Pathol 1989; 8 (4): 311-20.

  20. Martin KA, Rox Anderson R, Jeffrey Chang R, Ehrmann DA, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society. J Clin Endocrinol Metab 2018; 103 (4): 1233-57. doi: 10.1210/jc.2018-00241

  21. Cobin RH1, Futterweit W, Ginzburg SB, Goodman NF et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract 2006; 12(3): 315-37. doi: 10.4158/EP.12.3.315

  22. Adashi EY, Rock JA, Rosenwaks Z. Reproductive Endocrinology, Surgery, and Technology. Ed. Lippincott-Raven: Philadelphia,1996; 1257-69.

  23. Friedman CI, Schmidt GE, Kim MH, Powell J. Serum testosterone concentrations in the evaluation of androgenproducing tumors. Am J Obstet Gynecol 1985; 153 (1): 44-9. doi: 10.1016/0002-9378(85)90587-3.

  24. Rothman M, Wierman M. How should postmenopausal androgen excess be evaluated?. Clin Endocrinol (Oxf) 2011; 75 (2): 160-4. doi: 10.1111/j.1365-2265.2011.04040.x

  25. Dennedy M, Smith D, O'Shea D, McKenna T. Investigation of patients with atypical or severe hyperandrogenaemia including androgen-secreting ovarian teratoma. Eur J Endocrinol 2010; 162 (2): 213-20. doi: 10.1530/EJE-09-0576

  26. Brown DL, Henrichsen TL, Clayton AC, Hudson SB, Coddington CC, et al. Ovarian Stromal Hyperthecosis Sonographic Features and Histologic Associations. J Ultrasound Med 2009; 28 (5): 587-93. doi: 10.7863/jum.2009.28.5.587

  27. Rosenkrantz AB, Popiolek D, Bennett GL, Hecht EM. Magnetic Resonance Imaging Appearance of Ovarian Stromal Hyperplasia and Ovarian Hyperthecosis. J Comput Assist Tomogr 2009; 33 (6): 912-6. doi: 10.1097/RCT.0b013e3181a2ec0c

  28. Gressel G, Buza N, McCarthy S, Kodaman. Ovarian Stromal Hyperthecosis and Hyperandrogenemia Refractory to Hormonal Suppression. Obstet Gynecol Cases Rev 2015; 2: 6. doi: 10.23937/2377-9004/1410058

  29. Shim SH, Kim DY, Lee SW, Park JY, Kim JH, et al. Laparoscopic management of early-stage malignant nonepithelial ovarian tumors: surgical and survival outcomes. Int J Gynecol Cancer 2013; 23 (2): 249-55. doi: 10.1097/ IGC.0b013e318272e754

  30. Vollaard ES, van Beek AP, Verburg FA, Roos A, Land JA. Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin. J Clin Endocrinol Metab 2011; 96 (5): 1197-201. doi: 10.1210/jc.2010-1991

  31. Sielert L, Liu C, Nagarathinam R, Craig LB. Androgenproducing steroid cell ovarian tumor in a young woman and subsequent spontaneous pregnancy. J Assist Reprod Genet 2013; 30 (9): 1157-60. doi:10.1007/s10815-013-0051-9




2020     |     www.medigraphic.com